Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Key Inclusion Criteria:

• Participant has histologically or cytologically confirmed locally advanced (unresectable stage IIIB/C) or metastatic NSCLC (stage IV) with known subtype.

• Participant has progressed radiographically on or after receiving:

• One prior line of therapy (PD-1/PD-L1 inhibitor and platinum-based chemotherapyconcomitantly) in the locally advanced (unresectable stage IIIB/C) ormetastatic disease setting; OR

• No more than 2 prior lines of therapy (PD-1/PD-L1 inhibitor and platinum-basedchemotherapy sequentially, irrespective of the order) in the locally advanced (unresectable stage IIIB/C) or metastatic disease setting.

• Participant must have positive tumor PD-L1 expression (tumor cells ≥1%) determinedprospectively on a tumor sample from the locally advanced (unresectable stageIIIB/C) or metastatic setting at a sponsor-designated central laboratory.

• Participant has measurable disease according to RECIST v1.1 as assessed by theinvestigator at baseline.

• Participant has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 7 days of Cycle 1 Day 1.

• Participant has a life expectancy of ≥3 months.

• Participant must have adequate organ and bone marrow function, per laboratory testresults within 7 days of trial treatment.

Key Exclusion Criteria:

• Documentation of known targetable epidermal growth factor receptor (EGFR)sensitizing mutations, anaplastic lymphoma kinase (ALK), RET proto-oncogene (RET),ROS proto-oncogene 1; receptor tyrosine kinase (ROS1) rearrangement, Kirsten ratsarcoma virus (KRAS), B-Raf proto-oncogene (BRAF) mutations, and MET proto-oncogene;receptor tyrosine kinase (MET) exon 14 skipping mutations/MET amplification. NOTE:MET amplification testing is optional based on local availability of the test.

• Participants with known KRAS/BRAF mutations are eligible for the trial if theydo not have access to targeted therapies.

• Participants with newly identified, untreated or unstable or symptomatic centralnervous system (CNS) metastases or history of carcinomatous meningitis.

• Prior treatment with docetaxel for NSCLC.

• Prior treatment with a 4-1BB (CD137) targeted agent, any type of antitumor vaccine,autologous cell immunotherapy, or any unapproved immunotherapy.

• Treatment with an anticancer agent within 28 days prior to the first dose of trialtreatment.

Note: Other protocol-defined inclusion and exclusion criteria may apply.